Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression

Background Response to targeting and non-targeting agents is variable and molecular information remains poorly described in patients with recurrent sonic-hedgehog-driven medulloblastoma (SHH-MB). Materials and Methods Clinical and PET/CT findings during treatment with successive hedgehog antagonists and temozolomide monotherapies are described in a heavily pre-treated patient with recurrent extraneural metastases from PTCH1 mutated/ wild type smoothened (SMO) CNS SHH-MB. Molecular tests were prospectively performed in tissue from two extraneural sites at progression. Results Sustained clinical/metabolic response was obtained to vismodegib. At progression, itraconazole was ineffective, but salvage temozolomide treatment results in a response similar to vismodegib. At further progression, acquired SMO and PIK3CA mutations were identified in bone (G477L and H1047A, respectively) and epidural (L412P and H1065L, respectively) metastases. No response was observed with subsequent sonidegib treatment. Conclusions This is the first clinical report of recurrent extraneural PTCH1 mutated SHH-MB exhibiting: 1) a sustained response to vismodegib and temozolomide, and 2) inter-metastatic molecular heterogeneity and acquired SMO-G477L, SMO-L412P, and PIK3CA-H1065L mutations at progression, highlighting the need for a multitarget treatment approach.

[1]  T. MacDonald,et al.  Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma , 2017, Neuro-oncology.

[2]  L. Platanias,et al.  MEDU-44. TARGETING SHH SIGNALING VIA PI3K/MTOR INHIBITION IN MEDULLOBLASTOMA AND EWING SARCOMA , 2017 .

[3]  Gary D. Bader,et al.  Divergent clonal selection dominates medulloblastoma at recurrence , 2016, Nature.

[4]  K. Sarin,et al.  An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib , 2015, Clinical Cancer Research.

[5]  Jingwu Xie,et al.  Non-Canonical Hh Signaling in Cancer—Current Understanding and Future Directions , 2015, Cancers.

[6]  Michael C. Rusch,et al.  Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Brandes,et al.  New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. , 2015, Critical reviews in oncology/hematology.

[8]  R. Young,et al.  Extraneural metastases of medulloblastoma: Desmoplastic variants may have prolonged survival , 2015, Pediatric blood & cancer.

[9]  Jean Y. Tang,et al.  Smoothened variants explain the majority of drug resistance in basal cell carcinoma. , 2015, Cancer cell.

[10]  C. Rudin,et al.  Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. , 2015, Cancer cell.

[11]  Deena M. A. Gendoo,et al.  Medulloblastoma subgroups remain stable across primary and metastatic compartments , 2015, Acta Neuropathologica.

[12]  G. Perilongo,et al.  Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. , 2014, Neuro-oncology.

[13]  Roland Eils,et al.  Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. , 2014, Cancer cell.

[14]  P. Beachy,et al.  Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Dummer,et al.  A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[16]  David T. W. Jones,et al.  Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Kasper,et al.  Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma , 2013, Acta oncologica.

[18]  C. Rudin,et al.  Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. , 2013, Cancer cell.

[19]  Elaine R. Mardis,et al.  Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.

[20]  Stefan M. Pfister,et al.  The clinical implications of medulloblastoma subgroups , 2012, Nature Reviews Neurology.

[21]  David T. W. Jones,et al.  Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations , 2012, Cell.

[22]  M. Hegi,et al.  Expression of O6-methylguanine-DNA methyltransferase in childhood medulloblastoma , 2011, Journal of Neuro-Oncology.

[23]  Arie Perry,et al.  Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups , 2011, Acta Neuropathologica.

[24]  Z. Modrušan,et al.  Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. , 2011, Cancer research.

[25]  Jing Yuan,et al.  Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma , 2010, Science Translational Medicine.

[26]  Jun O. Liu,et al.  Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. , 2010, Cancer cell.

[27]  Jeremy Stinson,et al.  Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. , 2009, The New England journal of medicine.

[28]  C. Rudin,et al.  Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma , 2009, Science.

[29]  D. Figarella-Branger,et al.  Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: long-term results of MSFOP 98. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Irthum,et al.  Temozolomide Treatment of an Adult with a Relapsing Medulloblastoma , 2007, Cancer investigation.

[31]  C. Emerson,et al.  Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[33]  C. Kennard,et al.  Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. , 1993, European journal of cancer.